On July 24, 2026, FMR LLC – the parent company of Fidelity Investments – filed a public disclosure indicating a major change in the beneficial ownership of Structure Therapeutics Inc., a U.S. biotechnology firm. The filing, made under the Securities Exchange Act, signals that a new investor or group of investors now holds a material stake in the company. While the exact percentages were not released in the summary, the filing itself triggers a cascade of compliance obligations for any party that holds a significant interest in a U.S. corporation.

For Singapore, Hong Kong, and China-outbound founders contemplating a U.S. market entry, the event underscores two practical realities: first, U.S. benefi cial‑ownership disclosures are mandatory once an investor crosses the 5 % threshold; second, those disclosures can affect how your cross‑border structure is perceived by regulators, banks, and downstream investors. Understanding the filing mechanics – from Schedule 13D/13G requirements to the Corporate Transparency Act (CTA) Beneficial Ownership Information (BOI) reporting – is essential to avoid unintended tax exposure and to maintain clean capital‑raising credentials.

Below is a step‑by‑step checklist that founders can apply the moment an investment or equity transfer exceeds the 5 % trigger in a U.S. entity:

  • Identify the filing trigger. Once any person or entity, directly or indirectly, acquires 5 % or more of a class of common stock, the holder must file Schedule 13D within 10 days (or Schedule 13G within 45 days for passive investors).
  • Prepare the disclosure. The filing must list the acquirer’s name, address, citizenship, and the number of shares owned. For foreign investors, the form also requires the U.S. Taxpayer Identification Number (EIN or ITIN) and, if applicable, the foreign tax identification number.
  • CTA BOI reporting. Under the Corporate Transparency Act, any U.S. entity with at least 20 % ownership or 25 % voting power must submit BOI to FinCEN within 30 days of the change. The report includes the beneficial owner’s full legal name, date of birth, residential address, and a unique identifying number (passport, driver’s license, etc.).
  • Assess GILTI implications. If the foreign investor is a corporate shareholder, the U.S. earnings of Structure Therapeutics may be subject to Global Intangible Low‑Tax Income (GILTI) under Section 951A. The investor should evaluate whether a qualified high‑tax exemption applies, or whether a “check‑the‑box” election to treat the U.S. subsidiary as a disregarded entity is feasible.
  • Coordinate with tax counsel. The change may affect the foreign parent’s U.S. tax filing obligations (Form 5471, Form 926) and could alter the timing of foreign tax credits. Early engagement with an international tax advisor prevents surprise tax liabilities.

In many cross‑border groups, the holding company sits in Singapore, Hong Kong, or a low‑tax jurisdiction such as the BVI. A beneficial‑ownership shift in the U.S. operating subsidiary can inadvertently make the holding company a “U.S. shareholder” for GILTI purposes, even if the holding company itself does not own 10 % of the U.S. entity. This is why founders often consider a two‑tier holding structure: a domestic U.S. holding company (often a Delaware C‑Corp) owned by an offshore vehicle, which in turn is owned by the Singapore or Hong Kong parent. The intermediate U.S. holding can isolate GILTI exposure while still allowing the foreign parent to benefit from cash repatriation through intercompany services.

When the ownership change is disclosed publicly, market participants will scrutinize the new shareholder’s background. If the new investor is a sovereign wealth fund, a private equity house, or a strategic biotech partner, the perception of Structure Therapeutics may shift, affecting valuation and future financing rounds. For founders, this means that any subsequent equity raise must account for the new capital‑structure dynamics, and the cap table should be updated in real time to reflect the disclosed ownership percentages.

Beyond the immediate filing, there are downstream compliance items that can catch first‑time structurers off guard:

  • Delaware franchise tax. Any increase in authorized shares or capital may raise the franchise tax bill. The tax is calculated on either the authorized‑share method or the assumed‑par‑value method; the lower amount is payable.
  • EIN/ITIN acquisition. Foreign investors often need an EIN for the U.S. subsidiary before they can file 13D/13G. The application can be completed online (Form SS‑4) without a Social Security Number, but a “foreign entity” designation must be indicated.
  • ODI (Outbound Direct Investment) notifications. Chinese investors must file an ODI notice with the Ministry of Commerce (MOFCOM) and the State Administration of Foreign Exchange (SAFE) before increasing ownership in a U.S. company. The filing window closes 30 days after the investment, and failure to report can result in penalties.

Given these layers, the most efficient approach is to embed the compliance steps into the initial transaction checklist, rather than treating them as an after‑thought. The following diagram illustrates a best‑practice workflow for a typical Singapore‑based founder acquiring a 10 % stake in a U.S. biotech:

  • Pre‑deal due diligence → Identify CTA and Schedule 13 filing thresholds
  • Structure equity via a Singapore holding → Layer a Delaware C‑Corp as a vehicle
  • Obtain EIN for Delaware entity → Draft 13D/13G disclosure
  • Submit CTA BOI report within 30 days → File Form 5471 (if applicable)
  • Monitor GILTI exposure → Run quarterly GILTI projection models (partnered with LYU LLC for data analytics)

YZ CPA Advisory View

For Singapore, Hong Kong, and China-outbound founders, the FMR filing is a reminder that any material equity shift in a U.S. venture triggers immediate reporting obligations that can cascade into tax and governance exposure. Aligning your ownership structure with a Delaware C‑Corp layer and maintaining real‑time BOI compliance are the safest ways to protect both valuation and tax efficiency.

Founders who are still evaluating the optimal jurisdiction for their U.S. foothold should review our cross-border corporate structuring for SG and HK founders guide. It outlines the pros and cons of direct U.S. incorporation versus using a regional holding, and it includes a checklist for CTA, GILTI, and ODI compliance.

In addition, the upcoming capital raise for Structure Therapeutics may create a window for strategic investors to join the round. If you are positioning your company as a co‑investor, be prepared to file the required disclosures within the statutory windows and to document the source of funds according to both U.S. anti‑money‑laundering rules and Chinese outbound investment regulations.

Finally, keep an eye on the ongoing regulatory dialogue around beneficial‑ownership transparency. The U.S. Treasury has announced that the CTA reporting schedule will be tightened in 2027, shortening the 30‑day grace period for updates. Early adoption of robust BOI reporting processes will give your group a competitive edge when negotiating future financing or M&A transactions.

中文摘要

FMR LLC 披露了对 Structure Therapeutics 的重大受益所有权变动，提醒新进美国市场的创始人须及时完成 Schedule 13D/13G、CTA BOI 报告以及可能的 GILTI 税务评估，合理的持股结构和合规流程是避免税务与融资风险的关键。

2026年7月24日，富达投资母公司FMR LLC提交了一份公开披露文件，表明其对美国生物科技公司Structure Therapeutics Inc.的受益所有权发生了重大变动。该文件依据《证券交易法》提交，意味着新投资者或投资者团体现已持有该美国公司的重要股份。尽管摘要中未披露具体持股比例，但此次申报本身触发了一系列合规义务，适用于任何持有美国公司重大权益的当事方。

对于有意进入美国市场的新加坡、香港及中国内地出海创始人而言，这一事件揭示了两项实际现实：第一，一旦投资者跨越5%持股门槛，就必须进行美国受益所有权披露；第二，这些披露可能会影响监管机构、银行及下游投资者对您跨境架构的看法。理解申报机制——从Schedule 13D/13G要求到《公司透明度法案》(CTA)的受益所有权信息(BOI)报告——对于避免意外税务风险并保持融资信誉至关重要。

以下是一份分步检查清单，创始人可在对美国实体的投资或股权转让超过5%触发门槛时立即应用：

  • 识别申报触发点。一旦任何个人或实体直接或间接持有一类普通股5%或以上股份，持有人必须在10天内提交Schedule 13D（被动投资者可在45天内提交Schedule 13G）。
  • 准备披露文件。申报文件必须列明收购方的名称、地址、国籍以及持股数量。对于外国投资者，表格还需提供美国纳税人识别号（EIN或ITIN），并在适用情况下提供外国税务识别号。
  • CTA BOI报告。根据《公司透明度法案》，任何拥有至少20%所有权或25%表决权的美国实体必须在变更发生后30天内向FinCEN提交BOI报告。报告包括受益所有人的法定全名、出生日期、居住地址以及唯一身份识别号码（护照、驾照等）。
  • 评估GILTI影响。如果外国投资者是公司股东，Structure Therapeutics的美国收益可能需根据第951A条缴纳全球无形资产低税收入(GILTI)。投资者应评估是否符合高税豁免条件，或者是否可以选择“打勾”将美国子公司视为忽略实体。
  • 与税务顾问协调。所有权变更可能影响外国母公司的美国税务申报义务（Form 5471、Form 926），并可能改变外国税收抵免的时间安排。尽早与国际税务顾问沟通可避免意外税务负债。

在许多跨境集团中，控股公司设在新加坡、香港或BVI等低税管辖区。美国运营子公司的受益所有权变动可能会无意中使控股公司成为GILTI目的下的“美国股东”，即使控股公司本身并未持有美国实体10%的股份。这就是为什么创始人通常考虑两层控股结构：由离岸载体持有的美国境内控股公司（通常为特拉华州C-Corp），而该离岸载体又由新加坡或香港母公司持有。中间层的美国控股公司可以隔离GILTI风险，同时仍允许外国母公司通过关联公司服务实现现金回流。

当所有权变更公开披露后，市场参与者将审视新股东的背景。如果新投资者是主权财富基金、私募股权机构或战略生物技术合作伙伴，Structure Therapeutics的市场认知可能发生变化，从而影响估值及后续融资轮次。对于创始人而言，这意味着任何后续股权融资都必须考虑新的资本结构动态，并且股权结构表应实时更新以反映披露的持股比例。

除了直接申报之外，还有一些下游合规事项可能会让首次进行架构设计的创始人措手不及：

  • 特拉华州特许经营税。授权股份或资本的任何增加都可能提高特许经营税账单。该税按授权股份法或假设面值法计算，支付金额取两者中较低者。
  • EIN/ITIN获取。外国投资者通常需要先为美国子公司获取EIN，才能提交13D/13G。申请可通过在线完成（Form SS-4），无需社会安全号码，但必须注明“外国实体”类别。
  • 对外直接投资（ODI）备案。中国投资者在增加对美国公司的持股之前，必须向商务部(MOFCOM)和国家外汇管理局(SAFE)提交ODI备案。申报窗口在投资完成后30天内关闭，未报告可能导致处罚。

鉴于上述多层次要求，最有效的方法是将合规步骤嵌入初始交易检查清单中，而非事后才考虑。下图展示了典型的新加坡创始人收购美国生物科技公司10%股权的最佳实践工作流程：

  • 交易前尽职调查 → 识别CTA和Schedule 13申报门槛
  • 通过新加坡控股公司搭建股权架构 → 以特拉华州C-Corp作为中间载体
  • 为特拉华州实体获取EIN → 起草13D/13G披露文件
  • 30天内提交CTA BOI报告 → 提交Form 5471（如适用）
  • 监控GILTI风险 → 每季度运行GILTI预测模型（与LYU LLC合作进行数据分析）

YZ CPA 顾问观点

对于新加坡、香港及中国内地的出海创始人而言，FMR的申报提醒我们，美国企业任何重大的股权变动都会立即触发申报义务，进而可能引发税务与治理风险。将您的所有权结构与特拉华州C-Corp层级对齐，并保持实时的BOI合规，是保护估值和税务效率的最安全方式。

仍在评估美国立足点最优司法管辖区的创始人，可查阅我们的面向SG和HK创始人的跨境公司架构指南。该指南概述了直接在美国注册成立与使用区域性控股公司的利弊，并包含了CTA、GILTI和ODI合规检查清单。

此外，Structure Therapeutics即将进行的融资轮次可能为战略投资者提供参与窗口。如果您的公司正作为共同投资者入局，请准备好在法定时限内提交所需披露文件，并按照美国反洗钱规则及中国对外投资规定记录资金来源。

最后，请持续关注围绕受益所有权透明度的监管动态。美国财政部已宣布，CTA报告时间表将在2027年收紧，缩短30天的更新宽限期。尽早建立稳健的BOI报告流程，将为您的集团在未来融资或并购交易谈判中赢得竞争优势。

中文摘要

FMR LLC 披露了对 Structure Therapeutics 的重大受益所有权变动，提醒新进美国市场的创始人须及时完成 Schedule 13D/13G、CTA BOI 报告以及可能的 GILTI 税务评估，合理的持股结构和合规流程是避免税务与融资风险的关键。

Reference: Background from Kalkine Media. This is original YZ CPA Advisory analysis.